RT Journal Article
SR Electronic
A1 Kuznar, Wayne
T1 Trough DPP-4 Inhibition Differs between the Approved DPP-4 Inhibitors
JF MD Conference Express
YR 2013
FD SAGE Publications
VO 13
IS 17
SP 22
OP 23
DO 10.1177/155989771317014
UL http://mdc.sagepub.com/content/13/17/22.2.abstract
AB A pharmacodynamics study in patients with type 2 diabetes mellitus (T2DM) reveals that sitagliptin QD provides greater inhibition of dipeptidyl peptidase-4 (DPP-4) through the dosing interval (ie, measured at trough, 24 hours following the last morning dose) than either saxagliptin 5 mg QD or vildagliptin 50 mg QD and similar DPP-4 inhibition to vildagliptin 50 mg BID. The findings come from a randomized, placebo-controlled, open-label, crossover study.